455 related articles for article (PubMed ID: 27046797)
1. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
3. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.
Holland L; Warkentin TE; Refaai M; Crowther MA; Johnston MA; Sarode R
Transfusion; 2009 Jun; 49(6):1171-7. PubMed ID: 19210325
[TBL] [Abstract][Full Text] [Related]
4. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
Schwebach AA; Waybright RA; Johnson TJ
Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
6. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
[TBL] [Abstract][Full Text] [Related]
7. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
8. A new kid on the block: Outcomes with Kcentra 1 year after approval.
Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
[TBL] [Abstract][Full Text] [Related]
9. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding.
Quinlan DJ; Eikelboom JW; Weitz JI
Circulation; 2013 Sep; 128(11):1179-81. PubMed ID: 23935012
[No Abstract] [Full Text] [Related]
10. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
[TBL] [Abstract][Full Text] [Related]
11. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
[TBL] [Abstract][Full Text] [Related]
12. ACP Journal Club. 4F-PCC was noninferior to plasma in patients with acute major bleeding who needed urgent VKA reversal.
Lang E
Ann Intern Med; 2014 Apr; 160(8):JC6. PubMed ID: 24733223
[No Abstract] [Full Text] [Related]
13. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Pabinger I; Brenner B; Kalina U; Knaub S; Nagy A; Ostermann H;
J Thromb Haemost; 2008 Apr; 6(4):622-31. PubMed ID: 18208533
[TBL] [Abstract][Full Text] [Related]
14. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
[TBL] [Abstract][Full Text] [Related]
15. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
16. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding.
Evans G; Luddington R; Baglin T
Br J Haematol; 2001 Dec; 115(4):998-1001. PubMed ID: 11843839
[TBL] [Abstract][Full Text] [Related]
17. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital.
Bruce D; Nokes TJ
Crit Care; 2008; 12(4):R105. PubMed ID: 18706082
[TBL] [Abstract][Full Text] [Related]
18. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
20. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding.
Stewart WS; Pettit H
Am J Emerg Med; 2013 Aug; 31(8):1251-4. PubMed ID: 23763937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
